Dr. Saperstein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cedar Street
P.O. Box 208042
New Haven, CT 06520Phone+1 203-200-5180Fax+1 203-200-5170
Education & Training
- New York Presbyterian Hospital (Columbia Campus)Fellowship, Nuclear Radiology, 2000 - 2001
- New York Presbyterian Hospital (Columbia Campus)Residency, Radiology-Diagnostic, 1996 - 2000
- Stanford Health Care-Sponsored Stanford UniversityResidency, Surgery, 1993 - 1995
- Duke University School of MedicineClass of 1993
Certifications & Licensure
- CA State Medical License 1994 - Present
- CT State Medical License 2007 - 2025
- FL State Medical License 2006 - 2017
- NY State Medical License 1999 - 2013
- NJ State Medical License 2001 - 2009
- American Board of Nuclear Medicine Nuclear Medicine
- American Board of Radiology Diagnostic Radiology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
Publications & Presentations
PubMed
- Long-Term Outcomes of Prostate-Specific Membrane Antigen-PET Imaging of Recurrent Prostate Cancer.Natalia Kunst, Jessica B Long, Sarah Westvold, Preston C Sprenkle, Isaac Y Kim
JAMA Network Open. 2024-10-01 - 5 citationsPET Image Denoising using a Deep-Learning Method for Extremely Obese Patients.Hui Liu, Hamed Yousefi, Niloufar Mirian, MingDe Lin, David Menard
IEEE Transactions on Radiation and Plasma Medical Sciences. 2022-09-01 - Clinical PET/CT utilization during the COVID-19 pandemic: initial experience at Yale UniversityMehmet Emin Adin, Haruka Uezono, Edvin Isufi, Yulei Pang, William Zucconi
Nuclear Medicine Communications. 2021-11-01
Press Mentions
- Radiologists Bring New Molecular Imaging Technology to YaleJanuary 19th, 2021
- Phase 3 Trial Testing New Imaging Agent for Prostate Cancer Detection Doses First PatientDecember 12th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: